MET and hypertensive disorder: In our analysis, bioavailable compounds from ZXD were associated with 149 hypertension-related targets, including pivotal nodes such as SRC, PTPN11, EGFR, PIK3CA, PIK3CB, HRAS, NRAS, PDGFRA, IGF1R, and MET, highlighting the multi-target characteristics of the prescription.